AKT1 and diabetes mellitus: It is therefore logical to imply that FOXO3a activation competes with the JNK (probably via JNK2) and the PI3K/Akt signaling pathways, both of which have been shown to be reduced in well-controlled diabetes (Li et al. 2018a, b, c).